5 Jan 2024 , 11:32 AM
Lupin Limited’s shares hit a 52-week high of Rs 1,429.95 in early trade on January 5 after the company said that the US Food and medicine Administration (USFDA) had granted it preliminary permission to commercialize a generic diabetic medicine.
At around 11.03 AM, Lupin was trading 0.39% lower at Rs 1,393.55 per piece, against the previous close of Rs 1,399 on NSE.
The Mumbai-based company announced on January 4 that it has obtained approval from the American regulator for its abbreviated new drug application for dapagliflozin and saxagliptin tablets. The product serves as a generic counterpart to AstraZeneca AB’s Qtern tablets.
Lupin plans to manufacture the drug at its Pithampur Facility in Madhya Pradesh.
Dapagliflozin and saxagliptin tablets are used to enhance glycemic control in persons with type 2 diabetes in addition to diet and exercise.
The FDA approved the pharma company’s generic loteprednol etabonate ophthalmic fluid for seasonal allergic conjunctivitis in December.
Lupin Atlantis Holdings SA, Switzerland, a wholly-owned subsidiary of the firm, has agreed to purchase a portfolio of established pharmaceuticals in Europe and Canada from Sanofi, a French multinational pharmaceutical and healthcare company, for EUR 10 million (Rs 91 crore).
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.